Date: 2012-06-04
Type of information: Presentation of results at a congress
phase: 2
Announcement: presentation of results at the American Society of Clinical Oncology (ASCO) annual meeting, in Chicago
Company: MolMed (Italy)
Product: NGR-hTNF
Action
mechanism: protein. NGR-hTNF is a vascular targeting agent with unique mode of action, and a first-in-class compound in the class of peptide/cytokine complexes able to selectively target the tumour vasculature. It consists of a tumour homing peptide (NGR) that selectively binds tumour blood vessels, fused to the human Tumour Necrosis Factor (TNF). NGR- hTNF is undergoing clinical development both as monotherapy and in combination therapy, in a total of seven indications.
Disease: relapsed small-cell lung cancer
relapsed ovarian cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: MolMed has presented at the 48th ASCO Annual meeting long term follow-up of two phase II trials of NGR-hTNF in combination with doxorubicin for the treatment of relapsed small-cell lung cancer (ASCO poster 7085) and relapsed ovarian cancer (ASCO poster 5059). In these two relapsed tumours, the combination with doxorubicin induces long-lasting tumour regressions. In small-cell lung cancer, the antitumour activity of the combination is independent of prior tumour chemosensitivity and able to overcome the resistance to previous treatments, with similar response and survival rates in both resistant and sensitive patients. In ovarian cancer, 3-year follow-up data show prolonged survival in those patients who achieved early disease control and continued treatment (median > 18 months) compared with the patients who progressed early and discontinued treatment (median < 4 months). These results are the basis of the ongoing randomised Phase II trial aimed at assessing standard chemotherapy with or without NGR-hTNF in 100 patients resistant or refractory to first-line treatment.
